Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors by Clare J. Stones et al.
ORIGINAL RESEARCH ARTICLE
published: 08 May 2013
doi: 10.3389/fgene.2013.00066
Comparison of responses of human melanoma cell lines
to MEK and BRAF inhibitors
Clare J. Stones1,2, Ji Eun Kim2, Wayne R. Joseph2, Euphemia Leung2, Elaine S. Marshall2,
Graeme J. Finlay2, Andrew N. Shelling1 and Bruce C. Baguley2*
1 Department of Obstetrics and Gynaecology, The University of Auckland, Auckland, New Zealand
2 Auckland Cancer Society Research Centre, The University of Auckland, Auckland, New Zealand
Edited by:
Mike Eccles, University of Otago,
New Zealand
Reviewed by:
Josh Waterfall, National Institutes of
Health, USA
Paola Parrella, IRCCS Casa Sollievo
della Sofferenza, Italy
*Correspondence:
Bruce C. Baguley, Auckland Cancer
Society Research Centre, The
University of Auckland, Private Bag
92019, Auckland 1142, New Zealand.
e-mail: b.baguley@auckland.ac.nz
The NRAS and BRAF genes are frequently mutated in melanoma, suggesting that the
NRAS-BRAF-MEK-ERK signaling pathway is an important target for therapy. Two classes
of drugs, one targeting activated BRAF and one targeting MEK, are currently undergoing
clinical evaluation. We have analysed the NRAS and BRAF mutational status of a series of
44 early passage lines developed from New Zealand patients with metastatic melanoma.
41% of the lines analysed had BRAF mutations, 23% had NRAS mutations, and 36%
had neither. We then determined IC50 values (drug concentrations for 50% growth
inhibition) for CI-1040, a commonly used inhibitor of MEK kinase; trametinib, a clinical
agent targeting MEK kinase; and vemurafenib, an inhibitor of mutant BRAF kinase. Cell
lines with activating BRAF mutations were significantly more sensitive to vemurafenib
than lines with NRAS mutations or lines lacking either mutation (p < 0.001). IC50 values
for CI-1040 and trametinib were strongly correlated (r = 0.98) with trametinib showing
∼100-fold greater potency. Cell lines sensitive to vemurafenib were also sensitive to
CI-1040 and trametinib, but there was no relationship between IC50 values and NRAS
mutation status. A small number of lines lacking a BRAF mutation were sensitive to
CI-1040 but resistant to vemurafenib. We used western blotting to investigate the effect on
ERK phosphorylation of CI-1040 in four lines, of vemurafenib in two lines and of trametinib
in two lines. The results support the view that MEK inhibitors might be combined with
BRAF inhibitors in the treatment of melanomas with activated BRAF. The high sensitivity
to trametinib of some lines with wildtype BRAF status also suggests that MEK inhibitors
could have a therapeutic effect against some melanomas as single agents.
Keywords:mitogen-activated protein kinase pathway,melanoma treatment, NRAS, BRAF, MEK, ERK, vemurafenib,
trametinib
INTRODUCTION
Malignant melanoma is an important public health issue, partic-
ularly in Australia and New Zealand where the incidence rates
for melanoma are very high (Coory et al., 2006; Liang et al.,
2010). While early stage melanoma can usually be treated suc-
cessfully by surgery, metastatic melanoma has a poor survival
rate and is highly resistant to conventional cytotoxic chemother-
apy. Activating mutations in the BRAF gene have been reported
in 40–70% of melanomas and activating mutations in the NRAS
gene in another 10–30% (Davies et al., 2002). There is consider-
able interest in developing therapies targeting this pathway, and
clinical trials of drugs such as vemurafenib (PLX4032), which tar-
get mutant BRAF protein, have provided very promising results
with 81% of patients with BRAF mutant melanoma having clin-
ical responses in a Phase I trial (Flaherty et al., 2010). Since
preclinical studies indicate that BRAF inhibitors are ineffective
in melanomas lacking BRAF mutations and may even enhance
growth (Hatzivassiliou et al., 2012), advanced clinical trials of
vemurafenib and other BRAF inhibitors are being carried out
specifically in patients whose melanomas contain BRAF muta-
tions (Solit et al., 2006; Flaherty et al., 2010).
Resistance to BRAF inhibitors develops relatively rapidly
because of BRAF-independent activation of MEK and ERK
(Johannessen et al., 2010) and other chemotherapeutic
approaches will be necessary, both for melanomas lacking
mutant BRAF and for melanomas that have developed resistance.
The MEK protein, which functions downstream from BRAF,
is thus a further potential target (Johannessen et al., 2010).
Preclinical studies with MEK inhibitors reported that BRAF
mutant melanoma cells growing both in vitro and in vivo as
xenografts were more responsive to MEK inhibition than cell
lines with wild type BRAF status (Davies et al., 2002; Solit
et al., 2006). Furthermore, the new MEK inhibitor trametinib
(GSK1120212) has shown evidence of clinical efficacy against
melanoma (Falchook et al., 2012), and has shown survival
benefits in phase III trial (Flaherty et al., 2012).
In this study, we have characterized the BRAF andNRASmuta-
tion status of a series of melanoma cell lines developed from New
Zealand patients withmetastatic melanoma (Marshall et al., 1994;
Charters et al., 2011; Kim et al., 2012). We determined the IC50
values of these cell lines to CI-1040, a MEK inhibitor that has
been utilized extensively in preclinical studies (Sebolt-Leopold,
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2004) and compared these values to those for the mutant BRAF
inhibitor vemurafenib. For a subset of cell lines we determined
IC50 values for trametinib. Since rapid development of resistance
(within hours) through up-regulation of MEK pathway signaling
in the absence of BRAFmutations has been reported inmelanoma
cell lines (Friday et al., 2008), we have also measured in some cell
lines the time-dependent effects of CI-1040 and vemurafenib on
ERK phosphorylation.
MATERIALS AND METHODS
CELL LINES AND TISSUE CULTURE
New Zealand Melanoma (NZM) cell lines were derived from
metastatic tumors and developed at the Auckland Cancer Society
Research Centre, New Zealand. The cell lines were maintained
in α-MEM medium (Invitrogen), supplemented with 5% foetal
calf serum (Invitrogen), penicillin-streptomycin sulfate, and
insulin-transferrin-selenite, in a 37◦C incubator at 5% CO2
and O2. The final concentrations of the supplements in media
were 100 units/mL penicillin G, 100μg/mL streptomycin sul-
fate, 5μg/mL insulin, 5μg/mL transferrin, and 5 ng/mL sodium
selenite.
GENOMIC PROFILING OF CELL LINES
DNA from cell lines was sequenced for activating mutations in
NRAS exon 2 and 3 and BRAF exon 11 and 15. DNAwas extracted
using phenol-chloroform-isoamyl alcohol. Exons of interest were
amplified by PCR using Taq polymerase fromQiagen. The primer
sequences for BRAF exon 15 and NRAS exon 2 and 3 were
designed using DNA Star; the sequences are provided in Table 1.
The primers for BRAF exon 11 are from a published source
(Davies et al., 2002). The PCR conditions were as follows: an ini-
tial denaturation step at 95◦C for 5min, followed by 30 cycles
(BRAF exon 11) or 40 cycles (BRAF exon 15,NRAS exon 2 and 3)
consisting of denaturation at 95◦C for 1min, annealing at the
appropriate temperature for 1min, extension at 72◦C for 1min,
followed by a final extension step at 72◦C for 10min. The anneal-
ing temperatures for the PCR reactions were as follows: 60◦C for
BRAF exon 11, 56◦C for BRAF exon 15, 58◦C for NRAS exon 2,
and 60◦C for NRAS exon 3. Polyethylene glycol precipitation (Lis
and Schleif, 1975) was used to purify the NRAS exon 2 and 3 and
BRAF exon 15 PCR products. Enzymatic digestion of unused PCR
reaction ingredients by exonuclease 1 Affymetrix USB and shrimp
alkaline phosphatase Affymetrix USB was used to purify BRAF
exon 11.
The PCR products were sequenced using thermal cycle
sequencing, with Big Dye Terminator 3.1 chemistry (Applied
Biosystems). The sequencing cycle conditions were as follows:
an initial denaturation step at 95◦C for 5min followed by 25
amplification cycles of 1min each of denaturation at 95◦C,
annealing at 50◦C for 5min, and primer extension at 60◦C
for 4min. The sequencing products were purified by ethanol
precipitation and the sequences run on an Applied Biosystems
3130XL capillary sequencing machine at the Centre for Genomics
and Proteomics, University of Auckland. Mutations were con-
firmed by sequencing in the opposite direction using separately
amplified DNA.
DETERMINATIONOF IC50 VALUES
The sensitivity of the cell lines to inhibitors was measured using
a 3H-thymidine incorporation method (Marshall et al., 1992).
Melanoma cells were plated in 96 well plates at 1000 cells per well
and incubated overnight at 37◦C at 5% CO2 and O2. Drugs were
added and plates incubated for 5 days at 37◦C at 5% CO2 and O2.
3H-thymidine (0.04μCi/well), 5-fluorodeoxyuridine (0.1μM),
and thymidine (0.1μM)were added 6 h before harvesting the cul-
tures. To harvest, Pronase (2 mg/mL in 4mM EDTA in PBS) was
added per well for 1 h and the plates incubated at 37◦C at 5%
CO2 and O2, to detach the cells. The cells were transferred onto
Wallac glass fiber filter mats using a Tomtec cell harvester, and the
beta emission counted using a Wallac Trilux Microbeta scintilla-
tion counter. IC50 values (mean and SEM) were calculated using
SigmaPlot.
WESTERN BLOT ANALYSIS
Cells were plated in 6 well tissue culture plates (Falcon) at
2.5 × 105 cells per well and incubated overnight at 37◦C at 5%
O2 to allow the cells to attach. Drugs were added to the wells
on the following day and the cells were harvested at the indi-
cated time points using a lysis buffer containing phosphatase
and protease inhibitors (Cheng et al., 2004). The protein con-
centration of cell lysates was determined using the bicinchoninic
acid (BCA) assay and the lysates (50μg of protein per well)
were subjected to western blotting. The proteins were trans-
ferred to PVDF membranes and probed with antibodies for
Table 1 | BRAF and NRAS sequencing primers.
Gene and exon Primers Primer sequence Amplicon size Location on reference sequence
BRAF exon 11 Forward Davies et al. (2002) 271bp 140481587-140481567
Reverse Davies et al. (2002) 140481275-140481298
BRAF exon 15 Forward CACCTCATCCTAACACATTTCAAG 765bp 140453433-140453410
Reverse TTTCAACAGGGTACACAGAACAT 140452668-140452690
NRAS exon 2 Forward ATTAATCCGGTGTTTTTGCGTTCT 633bp 115258944-115258921
Reverse CATCTCTGAATCCTTTATCTCCAT 115258311-115258334
NRAS exon 3 Forward AACAGCACAAATAAAACAGTCCAG 799bp 115256971-115256948
Reverse GGTTCCAAGTCATTCCCAGTA 115256172-115256192
The reference sequences cited are NC_000007.13 (BRAF) and NC_000001.10 (NRAS).
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Table 2 | Genetic and IC50 data for NZM cell lines.
Cell BRAF BRAF NRAS NRAS CI-1040 Trametinib Vemurafenib
line status DNA status DNA IC50 (nM) IC50 (nM) IC50 (nM)
NZM1 wildtype WT wildtype WT <7.8 1600
NZM2 wildtype WT wildtype WT 8.7 0.48 150
NZM3 V600E GTG to GAG 600 wildtype WT 36 29
NZM4 V600E GTG to GAG 600 wildtype WT 33 0.36 17
NZM5 wildtype WT wildtype WT 16 0.84 255
NZM6 V600E GTG to GAG 600 wildtype WT 65 59
NZM7 V600E GTG to GAG 600 wildtype WT 38 0.85 33
NZM9 wildtype WT wildtype WT 72 1600
NZM10 wildtype WT Q61K CAA to AAA 61 23 0.63 2500
NZM11 V600E GTG to GAG 600 wildtype WT 120 15
NZM13 wildtype WT wildtype WT 1070
NZM14 V600K GTG to AAG 600 wildtype WT 10 0.33 85
NZM15 wildtype WT Q61K CAA to AAA 61 <7.8 1050
NZM17 wildtype WT Q61K CAA to AAA 61 430 2000
NZM19 wildtype WT wildtype WT 102 1600
NZM20 V600E GTG to GAG 600 wildtype WT 9.1 0.30 13
NZM21 wildtype WT wildtype WT 101 0.75
NZM22 wildtype WT wildtype WT 1410 10 1030
NZM23 wildtype WT wildtype WT 740 1040
NZM24 wildtype WT G12D GGT to GAT 12 21 760
NZM28 G469A L584F GGA to GCA 469 CTT wildtype WT 8.6 3.3
to TTT 584
NZM29 wildtype WT wildtype WT 710 900
NZM30 V600E GTG to GAG 600 wildtype WT 22 0.35 66
NZM31 V600E GTG to GAG 600 wildtype WT 17 47
NZM33 wildtype WT Q61R CAA to CGA 61 <7.8 0.36 2300
NZM34 V600E GTG to GAG 600 wildtype WT 64 72
NZM35 wildtype WT wildtype WT 520 2.3 1040
NZM36 wildtype WT wildtype WT 8.5 2000
NZM37 Ins T600 Ins ACA 600 wildtype WT 19 400
NZM38 V600E GTG to GAG 600 wildtype WT 99 55
NZM39 wildtype WT wildtype WT <7.8 0.35 1300
NZM40 wildtype WT Q61H CAA to CAT 61 790 5.5 590
NZM41 D594N TGA to TAA 594 wildtype WT 200 660
NZM43 V600K GTG to AAG 600 wildtype WT <7.8 170
NZM44 wildtype WT wildtype WT 140 2000
NZM45 wildtype WT Q61L CAA to CTA 61 170 510
NZM46 wildtype WT Q61H CAA to CAT 61 10 140
NZM48 wildtype WT Q61K CAA to AAA 61 34 550
NZM49 V600E GTG to GAG 600 wildtype WT 70 0.40 70
NZM55 V600E GTG to GAG 600 wildtype WT 28 3.8
NZM56 wildtype WT wildtype WT 90 1.0 590
NZM58 V600E GTG to GAG 600 wildtype WT 67 0.33 25
NZM61 wildtype WT wildtype WT 90 0.75 560
NZM63 wildtype WT G13L GGT to CGT 13 <7.8 0.31 920
p-ERK, total ERK, p-MEK, total MEK, p-AKT, total AKT, cyclin
D1 (all from Cell Signaling Technology), tubulin (Sigma) and
β-actin (Millipore). The western blots were photographed using
a LAS3000 Luminescent Image Analyzer (Fuji), and quantified
using Image J software.
RESULTS
BRAF AND NRAS MUTATIONS IN MELANOMA CELL LINES
Screening results for the 44 melanoma cell lines are shown in
Table 2. Thirteen lines (30%) had activating V600E and another
2 lines (5%) had activating V600K mutations. The NZM28 line
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contained a L584F amino acid substitution as well as a G469A
substitution, the NZM41 line contained a D594N mutation, and
the NZM37 had a Thr600ins mutation. The cell lines were also
evaluated for mutations of the NRAS gene; four lines (9%) had
a Q61K mutation, one a G12D mutation, one a G13L mutation,
two a Q61H mutation, and one a Q61R mutation. All the identi-
fiedmutations are described in theWelcome Trust COSMICDNA
mutation database.
SENSITIVITY OF MELANOMA LINES TO CI-1040, VEMURAFENIB AND
TRAMETINIB
The response of the melanoma cell lines to the MEK and BRAF
inhibitors was tested using IC50 assays and the results are shown in
Table 2 and Figure 1. The main study, with CI-1040 (Figure 1A),
showed a clustering of low IC50 values for CI-1040 and vemu-
rafenib for cell lines with activating BRAF mutations (V600E
and V600K). The NZM28 cell line, which contained both G469A
and L584F substitutions was very sensitive to both inhibitors and
thus fell into this cluster. On the other hand NZM37, with a
Thr600 insertion, and NZM41, with a D594N substitution, were
relatively insensitive to vemurafenib (Table 2). Lines with NRAS
mutations (Q61K, G12D, Q61H, and Q61R) were all resistant
to vemurafenib and there was no correlation between the pres-
ence of mutation and sensitivity to CI-1040. A smaller study
(Figure 1B) compared cell line sensitivity to trametinib. IC50
values for trametinib were highly correlated with those for CI-
1040 (r = 0.985) but trametinib was, on average, more than 100-
fold more potent. Clustering of IC50 values was again observed,
with all vemurafenib sensitive lines also showing sensitivity to
trametinib.
MODULATION OF ERK PHOSPHORYLATION IN RESPONSE TOMEK AND
BRAF INHIBITORS
In order to compare signaling changes in the ERK pathway
to inhibition of proliferation, we measured changes to ERK
phosphorylation induced by CI-1040, trametinib, and vemu-
rafenib in NZM22, which is NRAS and BRAF wildtype and
relatively resistant to all three inhibitors (Table 2), and in NZM4,
which is BRAF mutant and relatively sensitive to the three
inhibitors tested. ERK phosphorylation was more sensitive in
NZM4 cells than in NZM22 cells in response to both CI-1040
and vemurafenib at both the 1-h and 24-h time points (Figure 2).
Comparison of sensitivity to trametinib was also carried out but
both cell lines were sensitive to the lowest drug concentration
used.
ERK phosphorylation in response to CI-1040 was measured
for NZM41, which is moderately resistant (IC50 = 200 nM).
The phosphorylation status of MEK, which phosphorylates and
FIGURE 2 | Western blots showing changes in ERK phosphorylation 1
and 24h after addition of different concentrations of the MEK inhibitors
CI-1040 and trametinib, and the mutant BRAF inhibitor vemurafenib.
(A) NZM22 line (BRAF wild type). (B) NZM4 line (V600E BRAF).
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FIGURE 1 | Comparison of IC50 values for (A) CI-1040 vs. vemurafenib
and (B) trametinib vs. vemurafenib using a panel of melanoma cell lines.
Black circles: mutant BRAF. Yellow circles: mutant NRAS. White circles:
wildtype for BRAF and NRAS. Vertical and horizontal bars indicate the
standard errors of the means where available; IC50 values of <7.8 nM are
shown as 7.8 nM.
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FIGURE 3 | Western blots showing pathway signaling in response to
CI-1040 (nanomolar concentrations) for the NZM41 line (BRAF D549N
mutation) at 1 and 24h. The arrow indicates the protein of interest in
blots where non-specific bands are also present.
activates ERK, was measured for comparison. Since expression
of cyclin D1 has been reported to be down-regulated following
MEK inhibition in cells with BRAF V600E mutations (Pritchard
et al., 2007), expression of cyclin D1 was also measured, but there
was no change in expression. ERK phosphorylation was inhibited
at a CI-1040 concentration of 10 nM after 1 h but was compara-
tively unaffected after 24 h, even at 500 nM (Figure 3). This is in
agreement with a report that sensitivity to a MEK inhibitor may
decrease with exposure time (Friday et al., 2008). Interestingly,
NZM41 showed evidence of CI-1040 resistance since MEK phos-
phorylation was increased following exposure to CI-1040 at
500 nM after 1 h and even at 50 nM after 24 h (Figure 3). The
experiment was repeated with the NZM2 line, which is sensitive
to CI-1040 (IC50 = 8.7 nM) and wildtype for BRAF and NRAS.
ERK phosphorylation was highly sensitive to CI-1040 at both the
1-h and 24-h time points (Figure 4). No changes in MEK phos-
phorylation was observed but a decrease in cyclin D1 expression
was apparent after 24 h.
DISCUSSION
New Zealand has a high incidence of melanoma and it was there-
fore of interest to compare the frequencies of activating BRAF
and NRAS mutations in New Zealand-derived melanoma lines
with published values. The BRAF V600E mutation frequently
observed was found in this study at 30% (Table 2), lower than
that reported by other groups (Davies et al., 2002; Houben et al.,
2004; Edlundh-Rose et al., 2006; Thomas et al., 2007) while that
for V600K was 5%. The mutation frequency for NRAS was 23%
(Table 2), within the range reported by other groups (Davies
et al., 2002; Houben et al., 2004; Edlundh-Rose et al., 2006;
Thomas et al., 2007). The data in Figure 1 and Table 2 clearly
show that cell lines with activating V600E and V600K mutations
were generally sensitive to CI-1040, trametinib and vemurafenib
FIGURE 4 | Western blots showing pathway signaling in response to
CI-1040 (nanomolar concentrations) for the NZM2 line (BRAF wildtype)
at 1 and 24h. The arrows indicate the protein of interest in blots where
non-specific bands are also present.
inhibition. As shown in Table 2 the NZM28 cell line, which con-
tained both G469A and L584F substitutions, was very sensitive to
both inhibitors. SIFT algorithm analysis (Kumar et al., 2009) was
undertaken to provide an indication of the effect of mutation, and
predicted that the L584F mutation alters protein function, consis-
tent with this effect. On the other hand NZM37, with a Thr600
insertion and NZM41, with a D594N substitution, were rela-
tively insensitive to vemurafenib (Table 2), raising the question of
why they might be selected for during melanoma development.
The G469A mutation has been reported to have no enhancing
effect on BRAF (Smalley and Flaherty, 2009) but it has been
reported that kinase-dead BRAF mutations of D594 can have an
indirect effect on tumor progression by enhancing CRAF activ-
ity (Heidorn et al., 2010). Several other studies have explored the
relationship between mutation status and sensitivity toMEK inhi-
bition for a variety of tumor types including melanoma, breast,
ovarian, and lung cancers (Davies et al., 2002; Solit et al., 2006).
In these studies, cell lines with BRAF mutations were very sensi-
tive to MEK inhibition of cell growth while cell lines with NRAS
mutations showed a range of sensitivities, in agreement with the
present results.
It has been reported that either PI3K oncogenic mutations or
deletion of PTEN reduces sensitivity of cells to MEK inhibitors
(Wee et al., 2009). In this study, the NZM40 and NZM46 lines
were found to have an activated mutated PI3K enzyme and the
NZM6, NZM30, NZM34, and NZM43 lines were found to lack
PTEN expression (Kim et al., 2012). However, there was no clear
indication of altered sensitivity to CI-1040 among these cell lines.
There are also reports that up-regulation of MEK can lead to
reduced sensitivity of cells to MEK inhibitors (Friday et al., 2008).
We investigated ERK phosphorylation in a number of melanoma
lines (Figures 2–4). Although some evidence of loss of initial
sensitivity in resistant lines was found (Figure 3) the pattern of
phosphorylation results broadly followed that of the IC50 results.
In conclusion, we have assessed the responses of a series of 44
melanoma lines, generally of low passage number, to CI-1040,
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a prototypic MEK inhibitor, as well as to trametinib, a clinical
MEK inhibitor and vemurafenib, a clinical BRAF inhibitor. We
identified a sub-set of 16 lines (36%) with activating BRAFmuta-
tions (Figure 1) that showed sensitivity to both clinical inhibitors,
supporting the hypothesis that a combination of both BRAF
and MEK inhibitors might have advantages over either drug
alone because of potentially synergistic inhibitory effects on sig-
nal transduction. We also identified a second sub-set of 10 cell
lines (23%) that were resistant to vemurafenib but sensitive to
a MEK inhibitor. Some but not all of these cell lines exhibited
NRAS mutations, suggesting that some melanomas that are wild-
type for both BRAF andNRASmay respond to trametinib, aMEK
inhibitor. If this applies in vivo, then a proportion of melanoma
patients whose disease is resistant to BRAF inhibitor therapy may
respond to therapy with a MEK inhibitor.
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